A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : irAEs

Search Conditions:
Search Keyword : irAEs
Search Method : Exact match.
Research Area:

Results:  
Hit abbr.: 2 kinds.
(Click one to see its hit entries.)

(Appearance freq, Descending)
Abbreviation: irAEs
Appearance Frequency: 1615 time(s)
Long forms: 18

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
immune-related adverse events
(1567 times)
Neoplasms
(646 times)
ICIs (541 times)
NSCLC (167 times)
ICI (158 times)
1995 Pretreatment regimens for adverse events related to infusion of amphotericin B.
immune-related AEs
(23 times)
Neoplasms
(12 times)
AEs (19 times)
ICIs (7 times)
PD-1 (4 times)
2011 Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
immunotherapy-related adverse effects
(10 times)
Therapeutics
(3 times)
ICIs (2 times)
BMI (1 time)
CIs (1 time)
2016 Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.
ICIs are associated with unique immune mediated adverse events
(1 time)
Immunotherapy
(1 time)
ICIs (1 time)
2019 A case of checkpoint inhibitor-induced celiac disease.
ICIs-related adverse events
(1 time)
CI (1 time)
CIP (1 time)
ICIs (1 time)
2022 Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer.
ICPIs are associated with a wide spectrum ofimmune-related adverse events
(1 time)
ICPIs (1 time)
2020 Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis.
Immune adverse events
(1 time)
Immunotherapy
(1 time)
ipi3 (1 time)
OS (1 time)
RFS (1 time)
2021 Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
immune response adverse events
(1 time)
Drug Therapy
(1 time)
CAR (1 time)
NSCLC (1 time)
2016 Immunotherapy to Treat Cancer.
immune-reaction-based adverse events
(1 time)
Neoplasms
(1 time)
ICI (1 time)
MM (1 time)
SSM (1 time)
2021 Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases.
10  immune-related endocrine adverse events
(1 time)
Medicine
(1 time)
NSCLC (1 time)
PFS (1 time)
2021 Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
11  immune-related phenomena and adverse events
(1 time)
Neoplasms
(1 time)
ASCO (1 time)
2010 Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
12  immune-therapy related toxicity events
(1 time)
Immune System Diseases
(1 time)
--- 2021 Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.
13  immunotherapy +/- chemotherapy, at development of adverse events
(1 time)
Neoplasms
(1 time)
HC (1 time)
LC (1 time)
2021 Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
14  inflammatory responses
(1 time)
Allergy and Immunology
(1 time)
PBMCs (1 time)
2020 The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.
15  inflammatory side effects
(1 time)
ICIs (1 time)
NSCLC (1 time)
2022 Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge.
16  infusion-related adverse events
(1 time)
Cell Biology
(1 time)
DMSO (1 time)
HC (1 time)
2020 Cryopreservation of hematopoietic cells using a pre-constituted, protein-free cryopreservative solution with 5% dimethyl sulfoxide.
17  inhibitors related adverse effects
(1 time)
Neoplasms
(1 time)
ICIs (1 time)
2019 [The Use of Glucocorticoid in the Management of Adverse Effects Related to Immunocheckpoint Inhibitors].
18  ipilimumab causes a variety of autoimmune-related adverse events
(1 time)
ACTH (1 time)
CSF (1 time)
WBC (1 time)
2019 Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: A case report.